Day: April 5, 2024

Festi‘s Financial Calendar published on October 25, 2023, has been altered as follows:1Q 2024 23. April 2024 Q1 2024 Results2Q 2024 31. July 2024 Q2 2024 Results3Q 2024 30. October 2024 Q3 2024 Results4Q 2024 5. February 2025 Q4 2024 ResultsAGM 5. March 2025 General MeetingPlease note changed dates for the publication of the Q1 2024 Results, which will take place on April 23, 2024. The financial results will be published after closing of markets each day.   For further information, please contact Ásta S. Fjeldsted, CEO of Festi –  asta@festi.is or Magnús Kr. Ingason, CFO of Festi – mki@festi.is

Company Announcement no. 02-2024 Copenhagen, April 5, 2024  Swiss Properties Invest A/S gives notice to the Annual General Meeting Notice is hereby given to shareholders in Swiss Properties Invest A/S of the ordinary annual general meeting scheduled as follows: Date                Friday, 19th April 2024Time                14:00 (CET)Location          Skovshoved Hotel, Strandvejen 267, 2920 Charlottenlund, Denmark Enclosed you will find notice and agenda for the ordinary annual general meeting.   ABOUT SWISS PROPERTIES INVEST Swiss Properties Invest A/S, which was founded on 8 October 2021, is the Danish holding company of the wholly owned subsidiary Swiss Properties Invest AG (CHE-422.631.240), which was founded on 7 December 2021. The purpose of Swiss Properties Invest AG is to own, operate, optimize, and develop a portfolio of attractive...

Martela Corporation, Stock Exchange Release, 5.4.2024 at 12:00 Martela Corporation’s Annual General Meeting was held on Friday 5.4.2024. The Meeting approved the Financial Statements, discharged the members of the Board of Directors and CEO’s from liability for the year of 2023 and approved remuneration report and new remuneration policy . The Board of Directors proposal that no dividends would be paid was approved. The Annual General Meeting confirmed that the Board of Directors will consist of six members and Mr. Eero Martela, Ms. Hanna Mattila, Mr. Jan Mattsson, Mr. Johan Mild and Ms. Anni Vepsäläinen be re-elected as members of the Board of Directors and a new member Mr. Jacob Kragh. The Annual General Meeting resolved a monthly compensation of EUR 3,700 be paid for the Chairman of the Board and EUR 1,850 for the Board Members,...

5 April 2024 Company Announcement No. 11 Pharma Equity Group’s subsidiary, Reponex Pharmaceuticals A/S, reports highly positive final results from the phase-2 clinical trial of the company’s patented drug candidate RNX-051. Reponex Pharmaceuticals A/S (Reponex) today announced positive final results from the phase-2 clinical proof-of-concept trial of the drug candidate RNX-051, the MEFO trial, based on received high level summary from the Company’s clinical site. Reponex’s MEFO-trialThis concerns the treatment of patients with right-sided colon cancer and right-sided colon polyps/adenomas (precursors of cancer) with the Company’s drug candidate RNX-051. The company’s clinical collaborators who have performed the trial report the following: BackgroundPatients with precursor lesions to cancer in the colon (adenomas) harbor a different gut...

WiseEye™ AI is Driving AI Innovations for Battery-Powered Endpoint Applications TAINAN, Taiwan, April 05, 2024 (GLOBE NEWSWIRE) — Himax Technologies, Inc. (Nasdaq: HIMX) (“Himax” or “Company”), a leading supplier and fabless manufacturer of display drivers and other semiconductor products, today announced its participation in the embedded world Exhibition&Conference held in Nuremberg from April 9 to 11, 2024. Himax will showcase its WiseEyeTM applications and AI capabilities at the tinyML Pavilion booth, in collaboration with several ecosystem partners, through interactive demonstrations and expert-led discussions on-site. With Himax’s powerful AI and industry-leading ultralow power technology, battery powered endpoint AI devices can operate with a significantly extended battery life. The exhibition will feature...

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., April 05, 2024 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be presented at the upcoming American Association of Cancer Research (“AACR”) Annual Meeting 2024, taking place on April 5-10, 2024 in San Diego, California. Initial preclinical data will be presented for HMPL-506, a novel, highly potent and differentiated menin-MLL inhibitor for the treatment of certain types of acute leukemia. Compared with five other menin inhibitors in clinical development, HMPL-506 showed the stronger inhibitory potency in MLL-rearranged and NPM1 mutant leukemia cell line models. Furthermore, HMPL-506 in combination with azacytidine, venetoclax or gilteritinib...

Oslo, 5 April 2024: As announced in the fourth quarter 2023 financial report, Scatec has reorganised its segment reporting structure from 1 January 2024. The group’s revenues and operating expenses from the Services segment are now reported as part of the Power Production segment. The merger of the two segments results in an increase of Power Production EBITDA corresponding to the EBITDA previously reported in the Services segment. External revenues from Services are now included in revenues in the Power Production segment, and the net of internal revenues and operating expenses is part of Power Production operating expenses. The estimated increase in Power Production EBITDA for 2024 is 120-130 million, equalling the estimated outlook for Services presented in the fourth quarter 2023 financial report. Following the change, Scatec’s segment...

Serstech AB (publ) meddelar att årsredovisningen för 2023 nu finns tillgänglig på bolagets hemsida https://www.serstech.com/downloads/financial/Arsredovisning2023.pdf, samt som bilaga till detta pressmeddelande. För mer information: Stefan Sandor, VD Serstech ABTelefon: 0739-60 60 67E-post: ss@serstech.com eller Thomas Pileby, Styrelseordförande Serstech ABTelefon: 0702-07 26 43E-post: tp@serstech.com eller besök: www.serstech.com Certified advisor åt Serstech är Svensk Kapitalmarknadsgranskning AB (SKMG). Om SerstechSerstech utvecklare och säljer utrustning för identifiering av farliga kemikalier, såsom narkotika, bomber och kemiska stridsmedel. Bolagets kunder är huvudsakligen rättsvårdande myndigheter och inkluderar FN, Världstullorganisationen (WCO) och tull- och polismyndigheter över hela världen. Serstech har återförsäljare i 63...

Publication of annual report 2023 and convening notice for the General Meeting Regulatory release 5 April 2024, 8 a.m. CET Kinepolis Group presents its integrated annual report 2023, with a comprehensive overview of the Group’s strategic, financial, operational and ESG performance for the year 2023. The non-financial information section is available in Dutch, French and English. The financial report is available in Dutch and English. Link to the 2023 annual report. The Ordinary General Meeting will take place on Wednesday 8 May 2024 at 10 a.m. at the registered offices of Kinepolis Group NV (Eeuwfeestlaan 20, 1020 Brussels). Link to the reports, convening notice, proxy and other documents. Link to the ABN-AMRO platform to participate in the meeting. Contact Kinepolis Press Office                                        Kinepolis Investor...

The Supervisory Council of AS Tallinna Vesi approved the audited financial results for 2023. The financial results have not changed from the unaudited results published on 2 February 2024. The company’s sales revenue in 2023 was €61.14 million, compared to 2022, the sales revenue increased by 12.1%, or €6.58 million. The change in sales revenue was due to the tariff, adjusted by the increase in energy costs, which took effect on 01/10/2022. Revenue from the sale of water services increased by 13.8% to €55.62 million. The revenue from the sale of construction services was €4.77 million, which is 0.7% less than a year before.  Last year’s operating profit amounted to €17.35 million, almost recovering to 2021 levels and increasing by 53.3%, or €6.03 million, compared to the significantly lower base in 2022. The growth in operating profit...